GT Biopharma (GTBP) Convertible Debt (2013 - 2016)

GT Biopharma (GTBP) posted quarterly Convertible Debt of $400000.0 for Q3 2016, down 24.24% quarter-over-quarter from $528000.0 in Q2 2016.

GT Biopharma (GTBP) Convertible Debt (2013 - 2016) Analysis & Trends

GT Biopharma (GTBP) has reported Convertible Debt for 4 consecutive years, with $400000.0 the latest figure, recorded in Q3 2016.

In Q3 2016, Convertible Debt changed N/A year-over-year to $400000.0; the TTM figure through Sep 2016 stood at $400000.0 (changed N/A YoY), while the FY2015 annual figure was $714000.0, up 12.62% from the prior year.
Convertible Debt fell to $400000.0 in Q3 2016 per GTBP's latest filing, from $528000.0 in the prior quarter.
Across five years, Convertible Debt topped out at $714000.0 in Q4 2015 and bottomed at $97000.0 in Q4 2013.
Historically, Convertible Debt has averaged $436285.7 across 4 years, with a median of $528000.0 in 2016.
Annual changes were most pronounced in 2014 — Convertible Debt jumped 553.61% — and 2015, when it increased 12.62%.
GT Biopharma's Convertible Debt stood at $97000.0 in 2013, then surged by 553.61% to $634000.0 in 2014, then gained by 12.62% to $714000.0 in 2015, then tumbled by 43.98% to $400000.0 in 2016.
Business Quant data shows GTBP's Convertible Debt at $400000.0 in Q3 2016, $528000.0 in Q2 2016, and $553000.0 in Q1 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.75 Bn	130.90 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.96 Bn	77.96 Bn	3.93 Bn
3	Argenx Se	64.98 Bn	59.80 Bn	1.37 Bn
4	Moderna	56.33 Bn	51.19 Bn	52.00 Mn
5	BeOne Medicines	42.03 Bn	36.93 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.56 Bn	28.25 Bn	992.69 Mn
7	BioNTech SE	27.74 Bn	9.35 Bn	668.28 Mn
8	Insmed	27.47 Bn	26.31 Bn	358.27 Mn
9	Royalty Pharma	27.32 Bn	26.49 Bn	-
10	GT Biopharma	8.76 Mn	8.76 Mn	-

Download Data